Latest News

The approval is based on Lilly’s QWINT Phase III clinical programme, which evaluated insulin efsitora alfa-gobe in more than 3,400 adults with T2D across four registration studies.

Kenya’s 2026–2030 Health Products and Technologies Local Manufacturing Strategy targets local production of at least 50 per cent of the country’s essential health products.

Construction was completed in 2013 at a reported cost of nearly Sh200 million (US$1.54 million) through donor funding from the UAE-based Dar Al Ber Society.

The hospital, part of Aster DM Healthcare, also ranked second in the UAE and 253rd globally for Cardiology in Newsweek’s World’s Best Specialized Hospitals 2027.

The agreement comes as Novo continues to strengthen its position in cardiometabolic medicines, where longer dosing intervals are a growing focus of research and development.

The approval gives AbbVie another Parkinson’s product following its acquisition of Cerevel Therapeutics.

The withdrawal changes the immediate US regulatory path for the ES-SCLC indication, but the ongoing Phase III programme provides the companies with another source of clinical data.

The Pediatric Private Home Visits: Wellness and Vaccinations program covers routine services that support children’s health and development.

The company has developed an integrated value chain around cinchona cultivation, quinine production and pharmaceutical manufacturing, with malaria treatment forming an important part of its activities.

The facility adds domestic manufacturing capacity to the company’s operations as Kenya seeks to strengthen production of medical products within the country.